Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLT-NAT-HNMM-II: Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma
NCT07353073Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in head and neck mucosal melanoma (HNMM), sponsored by Shanghai Ninth People's Hospital. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
head and neck mucosal melanoma (HNMM)
Beyond the preview
Go deeper on NCT07353073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353073.